The Filing Desk

Agenus vs Monte Rosa Therapeutics

Agenus AGEN · Monte Rosa Therapeutics GLUE · Biotechnology

Monte Rosa Therapeutics reported revenue of $124 million in fiscal 2025, about the same as Agenus' $114 million in fiscal 2025. Agenus' revenue grew 10.4% in its latest year, and Monte Rosa Therapeutics' grew 63.5%. Agenus had an operating margin of -17.7%, against -43.8% at Monte Rosa Therapeutics. Free cash flow was −$77 million at Agenus and −$28 million at Monte Rosa Therapeutics.

Side by side

AgenusMonte Rosa Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$114M$124M
Revenue growth10.4%63.5%
Revenue growth a year, last 5 years5.3%—
Gross margin99.1%—
Operating margin−17.7%−43.8%
Net margin−2.7%−31.2%
Free cash flow−$77M−$28M
Free cash flow margin−67.6%−22.2%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count38.5%12.4%
Last close$6.14$8.91
P/E at the last close——
Insider trades, last 12 months—sold $4.0 million
Piotroski F-score3 of 9—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
AgenusMonte Rosa Therapeutics
Operating margin
Percent of revenue
AgenusMonte Rosa Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AgenusMonte Rosa Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Agenus and Monte Rosa Therapeutics pages.